CompletedNot Applicable

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

United States67 participantsStarted 2022-03-07

Plain-language summary

The objective of this application is to increase PrEP uptake among women vulnerable to HIV acquisition in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama. The investigators will use a mixed-methods approach to adapt and pilot test a patient-provider communication tool from the Centers for Disease Control and Prevention (CDC) PrEP toolkit that focuses on the first three steps of the PrEP cascade (e.g., recognizing HIV risk, identifying as a PrEP candidate, and interested in PrEP) to increase PrEP uptake via referrals to local PrEP clinics.

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion/Exclusion Criteria Patients * HIV-uninfected women * Age 18 years or older * English speaking * Report sexual activity or anticipate sexual activity within 6 months

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Intervention Feasibility: Enrollment Rates Among Eligible Patients Screened

Timeframe: Throughout recruitment period (approximately 24 months)

Intervention Feasibility: Intervention Completion Rates Among Enrolled Patients

Timeframe: Throughout recruitment period (approximately 24 months)

Intervention Feasibility: 3-month Follow-up Completion Rates Among Patients With Completed Intervention

Timeframe: Throughout recruitment and follow-up period (approximately 24 months)

Intervention Feasibility: PrEP Referral Acceptance Among Patients With Completed Intervention

Timeframe: Throughout recruitment period and follow-up period (approximately 24 months)

Intervention Acceptability: Client Satisfaction Among Patients With Completed Intervention

Timeframe: On intervention day, directly after intervention delivery

Preliminary Effectiveness: PrEP Uptake Among Eligible Patients Post-Intervention

Timeframe: Enrollment to 3 months post-intervention

Trial details

NCT IDNCT04373551

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

Results submitted2025-06-27

View on ClinicalTrials.gov More HIV-infection/AIDS trials